Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study

Josephine Collins, Yoav Mazor, Michael Jones, John Kellow, Allison Malcolm

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objective: To determine whether anorectal biofeedback therapy can improve the symptoms of fecal incontinence (FI) in patients with scleroderma when compared to patients with functional FI, and also whether there is any effect on anorectal physiology or quality of life (QOL). FI in patients with scleroderma is highly prevalent and is associated with significant loss of QOL. Biofeedback has been proven to be an effective treatment for functional FI, but there are no data to support its use in scleroderma. Materials and methods: 13 consecutive female patients (median age 59, IQR 47–65 years) with scleroderma, and 26 age- and parity-matched female patients with functional FI (disease controls, 2:1), underwent biofeedback therapy for management of FI. Fecal incontinence severity index (FISI), anorectal physiology, feeling of control and QOL were collected before and after 6 weeks of biofeedback therapy, with additional scoring repeated at 6-month follow-up. Results: After biofeedback treatment FISI, feeling of control and QOL significantly improved in both groups (p < 0.005). There was no difference in the degree in improvement in physiology, FISI or QOL between scleroderma patients and functional FI patients. Long-term improvement in FISI and control were seen in both groups and for QOL only in the scleroderma cohort (p < 0.05). Conclusions: Patients with scleroderma benefit from biofeedback therapy to the same extent as that achieved in patients with functional FI. There are significant improvements in symptoms, physiology and QOL. Biofeedback is an effective, low-risk treatment option in this patient group.

LanguageEnglish
Pages1433-1438
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume51
Issue number12
DOIs
Publication statusPublished - 1 Dec 2016

Fingerprint

Fecal Incontinence
Case-Control Studies
Quality of Life
Therapeutics
Biofeedback (Psychology)
Emotions
Parity

Keywords

  • Anorectal manometry
  • biofeedback
  • fecal incontinence
  • scleroderma
  • quality of life

Cite this

Collins, Josephine ; Mazor, Yoav ; Jones, Michael ; Kellow, John ; Malcolm, Allison. / Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence : a case-control study. In: Scandinavian Journal of Gastroenterology. 2016 ; Vol. 51, No. 12. pp. 1433-1438.
@article{644a2e094656418bbecb5811a396a5af,
title = "Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study",
abstract = "Objective: To determine whether anorectal biofeedback therapy can improve the symptoms of fecal incontinence (FI) in patients with scleroderma when compared to patients with functional FI, and also whether there is any effect on anorectal physiology or quality of life (QOL). FI in patients with scleroderma is highly prevalent and is associated with significant loss of QOL. Biofeedback has been proven to be an effective treatment for functional FI, but there are no data to support its use in scleroderma. Materials and methods: 13 consecutive female patients (median age 59, IQR 47–65 years) with scleroderma, and 26 age- and parity-matched female patients with functional FI (disease controls, 2:1), underwent biofeedback therapy for management of FI. Fecal incontinence severity index (FISI), anorectal physiology, feeling of control and QOL were collected before and after 6 weeks of biofeedback therapy, with additional scoring repeated at 6-month follow-up. Results: After biofeedback treatment FISI, feeling of control and QOL significantly improved in both groups (p < 0.005). There was no difference in the degree in improvement in physiology, FISI or QOL between scleroderma patients and functional FI patients. Long-term improvement in FISI and control were seen in both groups and for QOL only in the scleroderma cohort (p < 0.05). Conclusions: Patients with scleroderma benefit from biofeedback therapy to the same extent as that achieved in patients with functional FI. There are significant improvements in symptoms, physiology and QOL. Biofeedback is an effective, low-risk treatment option in this patient group.",
keywords = "Anorectal manometry, biofeedback, fecal incontinence, scleroderma, quality of life",
author = "Josephine Collins and Yoav Mazor and Michael Jones and John Kellow and Allison Malcolm",
year = "2016",
month = "12",
day = "1",
doi = "10.1080/00365521.2016.1218537",
language = "English",
volume = "51",
pages = "1433--1438",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "12",

}

Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence : a case-control study. / Collins, Josephine; Mazor, Yoav; Jones, Michael; Kellow, John; Malcolm, Allison.

In: Scandinavian Journal of Gastroenterology, Vol. 51, No. 12, 01.12.2016, p. 1433-1438.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence

T2 - Scandinavian Journal of Gastroenterology

AU - Collins, Josephine

AU - Mazor, Yoav

AU - Jones, Michael

AU - Kellow, John

AU - Malcolm, Allison

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objective: To determine whether anorectal biofeedback therapy can improve the symptoms of fecal incontinence (FI) in patients with scleroderma when compared to patients with functional FI, and also whether there is any effect on anorectal physiology or quality of life (QOL). FI in patients with scleroderma is highly prevalent and is associated with significant loss of QOL. Biofeedback has been proven to be an effective treatment for functional FI, but there are no data to support its use in scleroderma. Materials and methods: 13 consecutive female patients (median age 59, IQR 47–65 years) with scleroderma, and 26 age- and parity-matched female patients with functional FI (disease controls, 2:1), underwent biofeedback therapy for management of FI. Fecal incontinence severity index (FISI), anorectal physiology, feeling of control and QOL were collected before and after 6 weeks of biofeedback therapy, with additional scoring repeated at 6-month follow-up. Results: After biofeedback treatment FISI, feeling of control and QOL significantly improved in both groups (p < 0.005). There was no difference in the degree in improvement in physiology, FISI or QOL between scleroderma patients and functional FI patients. Long-term improvement in FISI and control were seen in both groups and for QOL only in the scleroderma cohort (p < 0.05). Conclusions: Patients with scleroderma benefit from biofeedback therapy to the same extent as that achieved in patients with functional FI. There are significant improvements in symptoms, physiology and QOL. Biofeedback is an effective, low-risk treatment option in this patient group.

AB - Objective: To determine whether anorectal biofeedback therapy can improve the symptoms of fecal incontinence (FI) in patients with scleroderma when compared to patients with functional FI, and also whether there is any effect on anorectal physiology or quality of life (QOL). FI in patients with scleroderma is highly prevalent and is associated with significant loss of QOL. Biofeedback has been proven to be an effective treatment for functional FI, but there are no data to support its use in scleroderma. Materials and methods: 13 consecutive female patients (median age 59, IQR 47–65 years) with scleroderma, and 26 age- and parity-matched female patients with functional FI (disease controls, 2:1), underwent biofeedback therapy for management of FI. Fecal incontinence severity index (FISI), anorectal physiology, feeling of control and QOL were collected before and after 6 weeks of biofeedback therapy, with additional scoring repeated at 6-month follow-up. Results: After biofeedback treatment FISI, feeling of control and QOL significantly improved in both groups (p < 0.005). There was no difference in the degree in improvement in physiology, FISI or QOL between scleroderma patients and functional FI patients. Long-term improvement in FISI and control were seen in both groups and for QOL only in the scleroderma cohort (p < 0.05). Conclusions: Patients with scleroderma benefit from biofeedback therapy to the same extent as that achieved in patients with functional FI. There are significant improvements in symptoms, physiology and QOL. Biofeedback is an effective, low-risk treatment option in this patient group.

KW - Anorectal manometry

KW - biofeedback

KW - fecal incontinence

KW - scleroderma

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84982163174&partnerID=8YFLogxK

U2 - 10.1080/00365521.2016.1218537

DO - 10.1080/00365521.2016.1218537

M3 - Article

VL - 51

SP - 1433

EP - 1438

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 12

ER -